文献速递膀胱癌与上尿路尿路上皮癌

晚期尿路上皮癌一线铂类化疗周期数对生存的影响

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
PubMed 文献 · J Urol · 2018-09-04

基于RISC回顾性数据库,比较转移性尿路上皮癌患者接受3–5周期与6–9周期一线铂类化疗的总生存,发现两组无显著差异(HR 1.02,95%CI 0.78–1.33,p=0.91),提示4周期左右可能已足够。

要点

  • 3–5周期与6–9周期铂类化疗的总生存无显著差异。
  • 铂类类型和计划化疗完成情况无显著交互作用。
  • 减少过多周期或可降低累积毒性并利于后续治疗转换。

核心结论

  • 一线铂类化疗4周期左右对晚期尿路上皮癌患者可能已足够,未显著损害生存。
  • 省略过多周期或可避免不必要的累积毒性,并利于向二线治疗或研究性维持治疗转换。

研究设计与样本

  • 回顾性国际研究RISC数据库分析,纳入接受顺铂或卡铂一线化疗的转移性尿路上皮癌患者。
  • 排除少于3周期或多于9周期者,主要分析采用6个月 landmark 法比较3–5周期与6–9周期的总生存。
  • 共1020例患者中472例接受顺铂或卡铂,可评估者分别为338例和134例。

主要发现

  • 157例接受3–5周期(中位4周期),315例接受6–9周期(中位6周期)。
  • 3–5周期与6–9周期总生存无显著差异(HR 1.02,95%CI 0.78–1.33,p=0.91)。
  • 铂类类型(p=0.09)和计划化疗完成情况(p=0.56)未见显著交互作用。

临床怎么用

  • 对适合的晚期尿路上皮癌患者,可考虑4周期左右一线铂类化疗后转换治疗,而非盲目延长周期。
  • 该结果需前瞻性验证,但可能影响特定患者的临床实践。

局限性

  • 为假设生成性回顾性分析,存在回顾性研究固有局限。
  • 结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the impact of the number of cycles of platinum based, first line chemotherapy (fewer than 6 cycles vs the conventional 6 cycles or more) on the survival of patients with metastatic urothelial carcinoma. MATERIALS AND METHODS: We used the RISC (Retrospective International Study of Invasive/Advanced Cancer of the Urothelium) database. The association of the number of cycles of chemotherapy with overall survival was investigated by Cox multiple regression analysis after controlling for recognized prognostic factors. We excluded patients who received fewer than 3 or more than 9 platinum chemotherapy cycles to reduce confounding factors. The primary analysis was a comparison of overall survival for 3 to 5 vs 6 to 9 cycles using 6-month landmark analysis when 281 death events were observed. RESULTS: Of the 1,020 patients in the RISC 472 received cisplatin or carboplatin, of whom 338 and 134, respectively, were evaluable. A total of 157 patients received 3 to 5 cycles (median 4) and 315 received 6 to 9 cycles (median 6). There was no significant difference in overall survival between 3 to 5 and 6 to 9 cycles (HR 1.02, 95% CI 0.78-1.33, p = 0.91). No significant interactions were observed for the type of platinum (p = 0.09) and completed planned chemotherapy (p = 0.56). The limitations of a hypothesis generating, retrospective analysis applied. CONCLUSIONS: Four cycles of platinum based, first line chemotherapy appeared adequate and did not significantly compromise the survival of patients with advanced urothelial carcinoma. The omission of excessive cycles may avoid unnecessary cumulative toxicity and facilitate a better transition to second line therapy and investigational switch maintenance therapy strategies. These results require prospective validation but they may impact practice in select patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Sonpavde GP, Mariani L, Lo Vullo S, et al. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. J Urol. 2018. PMID: 30012366. doi:10.1016/j.juro.2018.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。